ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.

Asymchem Laboratories (Tianjin) Co., Ltd.

002821

CNE100002BZ6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 07/06/2024 am IST			5-day change	1st Jan Change
74.11 ^CNY	-0.56%		-3.36%	-36.17%

06/06	Asymchem Laboratories Co., Ltd. Approves Final Ordinary Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024	CI
29/05	Asymchem Appoints Franck Mevellec as Senior Director, Business Development	CI

Asymchem Laboratories Co., Ltd. Declares Final Dividend for the Year Ended 31 December 2022. Payable on 21 July 2023

June 09, 2023 at 06:50 pm IST

Asymchem Laboratories (Tianjin) Co., Ltd. declared final dividend for the year ended 31 December 2022 of RMB 18 per 10 shares. Ex-dividend date is 15 June 2023, Record date is 27 June 2023 and payment date 21 July 2023.

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Asymchem Laboratories Co., Ltd. Approves Final Ordinary Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024	06/06	CI
Asymchem Appoints Franck Mevellec as Senior Director, Business Development	29/05	CI
Asymchem Laboratories Buys Pfizer's Former UK Site; Hong Kong Shares Slide 3%	23/05	MT
China-Based Asymchem Laboratories Will Operate Former Pfizer Manufacturing Facility in UK	21/05	DJ
Asymchem Laboratories Co., Ltd. Secures Former Pfizer Sandwich, UK, Development and API Pilot Plant Manufacturing Facilities	21/05	CI
Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3%	29/04	MT
Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy	26/04	MT
Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy	26/04	MT
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	02/04	CI
Asymchem Laboratories' Profit Falls 31% as Revenue Drops 24% in 2023	29/03	MT
Asymchem Laboratories Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023	28/03	CI
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Asymchem Laboratories Completes A-Share Repurchase Program	27/03	MT
Asymchem Laboratories Co., Ltd. commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024.	07/03	CI
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy	04/03	MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy	04/03	MT
Asymchem Laboratories Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024	29/02	CI
Asymchem Laboratories Co., Ltd. Announces Resignation of Wang Qingsong as Independent Non-Executive Director and Committees	05/02	CI
Asymchem's Shenzhen Shares Jump 7% on 1.2 Billion Yuan Stock Buyback	01/02	MT
INSTANT VIEW 8-China Evergrande ordered to liquidate by Hong Kong court	29/01	RE
Chinese Shares Retreat to Four-Year Lows Ahead of Trade, Inflation Data; Bolong Equipment Surges 17% in Shanghai Debut	10/01	MT
China's policy dilemma: is boosting credit deflationary?	10/01	RE
Asymchem Laboratories To Buy Back Over 100,000 Shares	26/12	MT
Chinese Shares End Lower as Economic Roadmap Disappoints; Fengmao Technology Surges 86% in Shenzhen Debut	13/12	MT

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Duration

Period

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

More charts

Company Profile

Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The Company's main businesses are the process development, amplification and commercialization of chemical drugs. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.

Sector

Pharmaceuticals

Calendar

15/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

74.11 CNY

Average target price

99.42 CNY

Spread / Average Target

+34.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.	-36.17%	351.34Cr
ELI LILLY AND COMPANY	+45.82%	77TCr
NOVO NORDISK A/S	+40.95%	63TCr
JOHNSON & JOHNSON	-6.16%	35TCr
MERCK & CO., INC.	+19.86%	33TCr
ABBVIE INC.	+9.32%	30TCr
ASTRAZENECA PLC	+18.45%	25TCr
ROCHE HOLDING AG	-0.78%	22TCr
NOVARTIS AG	+11.88%	22TCr
AMGEN INC.	+5.90%	16TCr

Other Pharmaceuticals

Asymchem Laboratories (Tianjin) Co., Ltd.

Equities

002821

CNE100002BZ6

Pharmaceuticals

Asymchem Laboratories Co., Ltd. Declares Final Dividend for the Year Ended 31 December 2022. Payable on 21 July 2023

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals